From snake venom to ACE inhibitor - The discovery and rise of captopril

Pharmaceutical Journal

Volumn 282, Issue 7548, 2009, Pages 455-456

  Bryan, Jenny ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CAPTOPRIL; CARBOXYPEPTIDASE A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PERINDOPRIL; SNAKE VENOM;

CLINICAL TRIAL; CONSENSUS; DRUG EFFECT; HEALTH PROGRAM; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; VASOCONSTRICTION;

EID: 77955886097     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. Erdös EG. The ACE and I: how ACE inhibitors came to be. The FASEB Journal 2006;20:1034-38.
2. Bakhle YS. Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature 1968;220:919-21.
3. Smith CG, Vane JR. The discovery of captopril. The FASEB Jounal 2003;17:788-9.
4. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 1991;17:589-92.
5. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S et al. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man. New England Journal of Medicine 1978;298,991-5.
6. Hoorntje SJ, Donker AJ. Clinical use of captopril. Hypertension 1981;3:507-8.
7. Cleland JGF, Dargie HJ, McAlpine H, Ball SG, Morton JJ, Robertson JIS et al. Severe hypotension after first dose of enalapril in heart failure. BMJ 1985;291:1309-12. (Pubitemid 16205378)
8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS).New England Jounal of Medicine 1987;316:1429-35.
9. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - results of the survival and ventricular enlargement trial. The SAVE Investigators. New England Journal of Medicine 1992;327:669-77.
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine 1992;327:685-91.
11. Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. New England Journal of Medicine 1986;315:847-53. (Pubitemid 16028479)
12. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM et al. Comparative effects of low and high doses of the angiotensin- converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8.